title: Efficacy of tranexamic acid in reducing blood loss after cesarean section.
abstract: OBJECTIVE
  To assess the efficacy and safety of tranexamic acid in reducing blood loss at caesarian section (CS).
  
  
  METHODS
  A prospective randomised study conducted on 90 primiparas divided into two groups who underwent CS. The study group, 45 women, received tranexamic acid immediately before CS, whereas the control group, 45 women received placebo. Blood loss volume was measured from the end of CS to 2 h postpartum and compared between the two groups. Hemoglobin (Hb) and hematocrit (Hct) were tested 24 h after CS and compared between the two groups.
  
  
  RESULTS
  Tranexamic acid significantly reduced the blood loss from the end of CS to 2 h postpartum; 28.02 +/- 5.53 mL in the tranexamic group versus 37.12 +/- 8.97 mL in the control group (p = 0.000). Hb 24 h after CS was significantly greater in tranexamic group than control group (12.57 +/- 1.33 in the tranexamic group and 11.74 +/- 1.14 in the control group, p = 0.002). No complications or side effects were reported in either group.
  
  
  CONCLUSIONS
  Tranexamic acid statistically reduces blood loss from end to 2 h after CS and its use was not associated with any side effects or complications. Consequently, tranexamic acid can be used safely and effectively to reduce bleeding resulting from CS.
authors.affiliation: Department of Obstetrics and Gynecology, Shahid Sedughi Hospital, Shahid Sedughi University of Medical Sciences and Health Services, Yazd, Iran. sekhavat@ssu.ac.ir
authors.forename: Leila
authors.initials: L
authors.lastname: Sekhavat
authors.forename: Afsar
authors.initials: A
authors.lastname: Tabatabaii
authors.forename: Maryam
authors.initials: M
authors.lastname: Dalili
authors.forename: Tahminah
authors.initials: T
authors.lastname: Farajkhoda
authors.forename: Atefah Dehghani
authors.initials: AD
authors.lastname: Tafti
mesh_terms: D000328:Adult; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002585:Cesarean Section / Q000534:rehabilitation; D005260:Female; D006801:Humans; D008991:Monitoring, Physiologic; D010919:Placebos; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D011247:Pregnancy; D011300:Preoperative Care / Q000009:adverse effects / Q000379:methods; D011644:Puerperal Disorders / Q000517:prevention & control; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014592:Uterine Hemorrhage / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D000933:Antifibrinolytic Agents; D010919:Placebos; D014148:Tranexamic Acid